When Narcan isn’t enough: what the CDC’s medetomidine advisory means for Arizona

On April 2, 2026, the Centers for Disease Control and Prevention and the White House Office of National Drug Control Policy issued a joint Health Advisory — an unusual move — about a veterinary tranquilizer called medetomidine that is showing up, fast, in the illicit fentanyl supply. Reports submitted to the National Forensic Laboratory Information System grew from 247 in 2023 to 2,616 in 2024 to 8,233 in 2025. That is a 33-fold increase in two years.

Most of those reports — 52% — are still concentrated in the Northeast, with 31% in the Midwest. Less than 1% are from the West. For Arizona, that “less than 1%” is the most important number in the advisory. It is a window. The state has time to learn from what Philadelphia and Chicago and New York are already living through. That window will close.

What medetomidine is, and why it changes how an overdose looks

Medetomidine is an alpha-2 adrenergic agonist — the same class as xylazine, but cleaner and more potent. Veterinarians use it to sedate dogs. It was never approved for human use. When it is mixed into fentanyl, two things happen at once: people get high faster, and their bodies hold onto the sedation for far longer than naloxone can reverse.

That second part is the safety crisis. Naloxone is an opioid antagonist. It only addresses the fentanyl. Someone who has overdosed on a fentanyl–medetomidine mix can come up enough to start breathing again, and still remain unresponsive, with a dangerously slow heart rate and a body temperature that keeps falling. Clinicians are reporting deep coma, profound bradycardia, hypothermia, and persistent unresponsiveness even after Narcan. The medical literature emerging in early 2026 — including a recent pharmacology review in Pharmaceuticals — is calling for poly-drug reversal protocols that the field does not yet have.

For people in recovery, for outreach workers, for families: the lesson is not that naloxone has stopped working. It is still the first, fastest thing you can do. The lesson is that 911 is the second thing you have to do, every time.

The withdrawal problem nobody is ready for

The other half of the medetomidine story is what happens when someone who has been physically dependent on it tries to stop. Filter Magazine’s coverage of the advisory is blunt about it: the withdrawal can be life-threatening on its own. People are showing up in emergency departments with hypertensive crises, severe agitation, and autonomic instability that does not respond to standard opioid-withdrawal protocols. ICU admission has been required in a number of cases. Most treatment programs in the country have never seen this. Most programs in Arizona have not, either.

This is the gap that recovery navigation has to start closing. Someone in active use rarely chooses an adulterant. They get whatever the supply is. When they decide to stop, the program they walk into needs to know what they may be withdrawing from. Right now, in most of the country, that translation between street-supply intelligence and clinical intake does not happen.

What harm-reduction infrastructure can — and cannot — do

The medetomidine spread is also a stress test for drug checking. Test strips that work for xylazine are being evaluated for cross-reactivity with medetomidine; the most recent peer-reviewed performance data on xylazine strips, out of Los Angeles, found roughly 54% sensitivity at the concentrations actually present in the supply. That is not enough to be a reliable individual-protection tool. It is enough, used at scale, to be a reliable surveillance tool — which is how syringe service programs are already using it.

Distribution infrastructure is also catching up to the moment. Travis County, Texas is installing 13 new naloxone vending machines this spring. California’s CalRx program is now selling generic OTC Narcan for $19, a >50% price drop. These are exactly the kinds of community access channels the AZ Hikma settlement naloxone shipment, scheduled for September, can plug into.

California’s CalRx program is now selling generic OTC Narcan for $19, a >50% price drop.

What this means for Arizona’s launch year

The medetomidine spread is, for Arizona, both a head start and a deadline. The geography is on Arizona’s side for now. The clinical knowledge gap is not. If the West follows the Northeast pattern — and the Johns Hopkins systematic assessment suggests it will — Arizona will be looking at this within 12 to 18 months. The state can decide now whether its detox programs, ER staff, syringe service programs, and recovery navigation tools are ready, or whether they will be learning in real time the way other regions did with xylazine.

For the people Rize is built to serve, the practical takeaways are simpler.

If you witness an overdose: give naloxone, call 911, start rescue breathing. Stay until help arrives. Someone may not “wake up” the way they used to.

If you or someone you love uses fentanyl: getting a few doses of free naloxone, knowing where the nearest vending machine or pharmacy is, and knowing the number for the Arizona 988 line and for SAMHSA’s National Helpline at 1-800-662-HELP is a baseline. None of those things require disclosure to anyone you don’t choose.

If you are a provider in Arizona: the medetomidine literature is small but growing. The CDC Situation Summary is the cleanest single-page primer. Train your staff before the case comes through your door.

Why this matters for people in recovery

Recovery does not happen in a vacuum. The drug supply changes, sometimes faster than the systems built to support recovery can adapt. A person who chooses to stop today is making that choice in a market that did not exist three years ago. They deserve a navigation system that knows that — that does not assume “fentanyl” is a single, stable thing — and that connects them to the right level of care for what they are actually withdrawing from.

That is the version of recovery navigation Rize is building. If you are looking for help right now in Arizona, start at rizerecovery.org. If you are a family member or friend trying to figure out what to do next, our family resources are designed for you. And if you are a treatment provider who wants to be part of a navigation network that flags this kind of clinical signal early, we want to hear from you.

If you or someone you know is in immediate danger, call 911 or 988.